secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pulmatrix, Inc. (PULM)
CIK:        0001574235
Form:       8-K
Filed at:   2023-03-30T23:59:59+00:00
Accession:  0001493152-23-009607
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulmatrix reports FY2022 revenue $6.1M, net loss $18.8M; cash $35.6M into Q2 2024
--------------------------------------------------------------------------------

- Revenue $6.1M (+$0.9M YoY); net loss $18.8M vs $20.2M; EPS -$5.46 vs -$8.63.
- Cash $35.6M at Dec 31, 2022; runway into Q2 2024.
- PUR1900 Phase 2b in ABPA dosed first patients in Q1 2023; topline data expected mid-2024.
- PUR3100 Phase 1 for acute migraine positive: lower nausea vs IV DHE; plans for Phase 2.
- PUR1800 Phase 1b data presented; analysis ongoing for potential Phase 2 study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1574235/000149315223009607/0001493152-23-009607-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1574235/000149315223009607/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-009607

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer